Orthotopic and metastasis models for preclinical efficacy testing of novel cancer drugs
White Paper | Pharmatest Services Ltd
This Pharmatest White Paper addresses the lack of efficacy that is a major cause of attrition in clinical development of new oncology compounds by showing how selecting the correct and the most predictive animal models for research is critical before entering clinical efficacy studies.
It discusses the key factors in model selection including assessing the tumor microenvironment, testing immunomodulatory drugs in intact immune systems, testing compounds in metastasized disease and evaluating potential adverse effects in treatment-induced bone loss.
It also presents an array of cancer and skeletal disease models that take into account these crucial elements in developing novel antitumor therapies, allowing efficacy testing of compounds in broad experimental settings with improved clinical predictivity.